Antiviral activity and possible mode of action of ellagic acid identified in Lagerstroemia speciosa leaves toward human rhinoviruses
© Park et al.; licensee BioMed Central Ltd. 2014
Received: 10 February 2014
Accepted: 21 May 2014
Published: 26 May 2014
Human rhinoviruses (HRVs) are responsible for more than half of all cases of the common cold and cause billions of USD annually in medical visits and school and work absenteeism. An assessment was made of the cytotoxic and antiviral activities and possible mode of action of the tannin ellagic acid from the leaves of Lagerstroemia speciosa toward HeLa cells and three rhinoviruses, HRV-2, -3, and -4.
The antiviral property and mechanism of action of ellagic acid were evaluated using a sulforhodamine B assay and real-time reverse transcription-PCR (RT-PCR) with SYBR Green dye. Results were compared with those of the currently used broad-spectrum antiviral agent, ribavirin.
As judged by 50% inhibitory concentration values, natural ellagic acid was 1.8, 2.3, and 2.2 times more toxic toward HRV-2 (38 μg/mL), HRV-3 (31 μg/mL), and HRV-4 (29 μg/mL) than ribavirin, respectively. The inhibition rate of preincubation with 50 μg/mL ellagic acid was 17%, whereas continuous presence of ellagic acid during infection led to a significant increase in the inhibition (70%). Treatment with 50 μg/mL ellagic acid considerably suppressed HRV-4 infection only when added just after the virus inoculation (0 h) (87% inhibition), but not before -1 h or after 1 h or later (<20% inhibition). These findings suggest that ellagic acid does not interact with the HRV-4 particles and may directly interact with the human cells in the early stage of HRV infections to protect the cells from the virus destruction. Furthermore, RT-PCR analysis revealed that 50 μg/mL ellagic acid strongly inhibited the RNA replication of HRV-4 in HeLa cells, suggesting that ellagic acid inhibits virus replication by targeting on cellular molecules, rather than virus molecules.
Global efforts to reduce the level of antibiotics justify further studies on L. speciosa leaf-derived materials containing ellagic acid as potential anti-HRV products or a lead molecule for the prevention or treatment of HRV infection.
KeywordsHuman rhinovirus Natural antiviral agent Lagerstroemia speciosa Ellagic acid Tannin Cytotoxicity Selectivity RNA replication
Human rhinoviruses (HRVs) (Picornaviridae) are the most frequent cause of mild upper respiratory tract infection, or common cold. They are responsible for more than half of all cases of the common cold[1, 2]. HRVs are also associated with more severe diseases such as acute otitis media in children and sinusitis in adults. HRVs can also cause severe lower respiratory tract infections such as pneumonia, wheezing, bronchiolitis, and exacerbations of asthma and chronic obstructive pulmonary disease in infants and children as well as fatal pneumonia in elderly and immunocompromised adults. Although HRV-induced upper respiratory illness is often mild and self-limiting, the socioeconomic impact caused by medical visits and school and work absenteeism by HRV infection is considerable and the degree of inappropriate antibiotic use is significant[2, 8, 9]. More than 100 serotypes of HRV become an obstacle of development of a unifying vaccine. There is, therefore, a high need for the development of selective antiviral agents with novel target sites to establish an effective HRV management strategy and tactics because there are currently no approved antiviral therapies for the prevention or treatment of HRV infection.
Plants have been suggested as alternative sources for antiviral products largely because they constitute a potential source of bioactive secondary substances that have been perceived by the general public as relatively safe, with minimal impacts to human health, and often act at multiple and novel target sites[11–14]. Much effort has been focused on plants and their constituents as potential sources of commercial antiviral products for prevention or treatment of HRV infection. In the screening of plants for anti-HRV activity, a methanol extract from the leaves of Giant Crape-myrtle (called banaba in the Phillippines), Lagerstroemia speciosa (L.) Pers. (Lythraceae), was shown to have good antiviral activity toward HRV-4. Very little information has been done to consider potential use of L. speciosa to manage HRV, although the plant leaves possess antidiabetic and hypoglycemic, antiobesity, antioxidant, antigout, antiinflammatory, and antibacterial activities.
The aim of the study was to assess the cytotoxic and antiviral effects on HeLa cells and three HRV serotypes (HRV-2, HRV-3, and HRV-4) of the tannin ellagic acid from L. speciosa leaves, compared to commercial pure ellagic acid and ribavirin, a currently used broad-spectrum antiviral agent. The antiviral property and mechanisms of action of the constituent were elucidated using sulforhodamine B (SRB) assay and real-time reverse transcription-PCR with SYBR Green dye.
1H and 13C NMR spectra were recorded in DMSO-d 6 on a JNM-ECX 400 spectrometer (Jeol, Tokyo, Japan) at 400 and 100 MHz, respectively, using tetramethylsilane as an internal standard, and chemical shifts are given in δ (ppm). UV spectra were obtained in methanol on a BioMate 5 spectrophotometer (Thermo Spectronic, Rochester, NY), Fourier transform infrared (FT-IR) spectra on a Nicolet Magna 550 series II spectrometer (Midac, Atlanta, GA), and mass spectra on a Jeol GSX 400 spectrometer. Silica gel 60 (0.063–0.2 mm) (Merck, Darmstadt, Germany) was used for column chromatography. Merck precoated silica gel plates (Kieselgel 60 F254, 0.20 mm) were used for analytical thin-layer chromatography (TLC). A SCL-10 AVP high-performance liquid chromatograph (Shimadzu, Kyoto, Japan) was used for isolation of active principles.
Commercially available pure ellagic acid (≥95% purity) and SRB were purchased from Sigma-Aldrich (St. Louis, MO). The antiviral agent ribavirin was supplied by Tokyo Chemical Industry (Tokyo). Anitbiotic-antimycotic and minimum essential medium (MEM) were purchased from Invitrogen (Grand Island, NY). Fetal bovine serum was supplied by PAA Laboratories (Etobicoke, Ontario, Canada). All of the other chemicals and reagents used in this study were of analytical grade quality and available commercially.
Human rhinovirus serotypes and cell line
HeLa (ATCC CCL-2), a human epithelial adenocarcinoma cervix cell line, was purchased from the American Type Culture Collection (ATCC) (Manassas, VA). The cell line was maintained in MEM supplemented with 10% fetal bovine serum and 0.01% antibiotic-antimycotic in a humidified incubator at 37°C and 5% CO2. HRV-2 (ATCC VR-1112AS/GP), HRV-3 (ATCC VR-1113), and HRV-4 (ATCC VR-1114AS/GP) were purchased from ATCC. The three HRVs were propagated in HeLa cells at 37°C. Virus titers were determined by cytopathic effects (CPE) in HeLa cells and were expressed as 50% cell culture infective dose (CCID50) per mL as described previously[22, 23].
Air-dried leaves of L. speciosa were purchased from a local Giant Crape-myrtle farm in the Philippines. A certified botanical taxonomist was used to identify the plant. A voucher specimen (LS-1 L) was deposited in the Research Institute of Agriculture and Life Sciences, College of Agriculture and Life Sciences, Seoul National University.
Bioassay-guided fractionation and isolation
Air-dried leaves (2 kg) of L. speciosa were pulverized, extracted with methanol (2 × 10 L) at room temperature for 2 days, and filtered. The combined filtrate was concentrated to dryness by rotary evaporation at 40°C to yield 112 g of a dark greenish powder. The extract (100 g) was sequentially partitioned into hexane- (9.35 g), ethyl acetate- (14.4 g), butanol- (39.35 g), and water-soluble (36.9 g) portions for subsequent bioassay. The organic solvent-soluble portions were concentrated under vacuum at 40°C and water-soluble portion was concentrated at 50°C. For isolation of active principles, viral CPE inhibition assay described previously[22, 23] toward HRV-4 in HeLa cell was used.
Cytotoxicity and antiviral activity of fractions obtained from the solvent partitionings of the methanol extract of L. speciosa leaves toward human rhinovirus-4 in HeLa cells using sulforhodamine B bioassay
82 ± 1.8d
777 ± 5.8b
Ethyl acetate-soluble fraction
71 ± 1.0d
881 ± 8.7a
607 ± 3.5c
The antiviral activity of L. speciosa leaf-derived materials toward three HRVs tested was evaluated by the SRB method using CPE reduction[22, 23]. In brief, HeLa cells were seeded onto a 96-well microtiter plate at a concentration of 3 × 104 cells per well for 1 day. The culture medium was then removed, and the plates were washed with 1 × phosphate-buffered saline (PBS) (pH 7.3). Subsequently, 90 μL of diluted virus suspension containing CCID50 of the virus stock was added to produce an appropriate CPE within 2 days after infection, followed by the addition of 10 μL of MEM supplemented with 30 mM MgCl2 containing four to five concentrations of each test material in 0.1% dimethylsulfoxide (DMSO), based on the preliminary test results. The culture plates were incubated at 37°C and 5% CO2 for 2 days. After washing with 1 × PBS, 100 μL of 70% cold acetone were added to each well and left for 30 min at -20°C. After acetone solution was removed, the plates were left in a dry oven. A volume of 100 μL of 0.057% (w/v) SRB in 1% acetic acid solution was added to each well and left at room temperature for 30 min. Unbound SRB was removed and the plates were washed five times with 1% acetic acid before drying and were then left in a dry oven for 1 day. Bound SRB was solubilized with 100 μL of 10 mM unbuffered Tris-base solution and plates were left on a table for 30 min. Absorbance was read at 562 nm by using a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA) with a reference absorbance at 620 nm. Ribavirin served as a positive control and was similarly prepared. Negative controls consisted of the DMSO solution. Viral inhibition rate (%) was calculated using the following formula: (OD tV – OD cV)/(OD cd – OD cV) × 100, where OD tV is the optical density measured with a given concentration of the test material in HRV infected cells; OD cV is the optical density measured for the control untreated HRV infected cells; OD cd is the optical density measured for the control untreated HRV uninfected cells.
HeLa cells were seeded onto a 96-well microtiter plate as stated previously. The culture medium was removed and the plates were replaced with media containing different concentrations of the test materials in DMSO, based on the preliminary test results. After incubation at 37°C with 5% CO2 for 2 days, the cytotoxicity of the test materials to HeLa cells was evaluated using a SRB assay[22, 23] as stated previously.
Infectivity of HRV particles
The effects of ellagic acid and ribavirin on the infectivity of HRV-4 particles were evaluated as described previously by Choi et al.. Approximately twofold quantities of the IC50 values of each test compound were applied. HRV-4 was preincubated with 50 μg/mL ellagic acid or 100 μg/mL ribavirin for 1 h at 4°C. Monolayers of HeLa cells were infected with the pretreated or untreated HRV-4 for 1 h at 37°C. Unbound virus was removed by washing the wells with 2 × PBS, and then cells were incubated in fresh medium supplemented with or without test compound at 37°C. After 2 days, SRB test and antiviral activity were carried out as stated previously.
The time-of-addition effects of ellagic acid were tested according to the method of Choi et al.. In brief, monolayers of HeLa cells were seeded onto a 96-well microtiter plate as stated previously. After washing with 1 × PBS, 50 μg/mL ellagic acid were added onto the culture cells at before (-1 h), during (0 h), or after (1, 2, 4, and 6 h) HRV-4 infection at 37°C. Ribavirin served as a positive control and was similarly prepared. After 2 days, SRB test and antiviral activity were carried out as stated previously.
Reverse transcription-PCR analysis
To evaluate the level of gene expression, quantitative real-time reverse transcription-PCR (RT-PCR) with SYBR Green dye was performed. HRV-4 infected and noninfected cultures of HeLa cells grown in Corning 25 cm2 cell culture flasks (Corning, NY) were treated with 50 μg/mL ellagic acid or 100 μg/mL ribavirin. After incubation at 37°C and 5% CO2 for 2 days, total RNA was extracted from the culture cells using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Contaminated genomic DNA was removed using RQ1 RNase-free DNase (Promega, Madison, WI). Complementary DNA was synthesized using 1 μg total RNA through a reverse transcription reaction using the SuperScript First-Strand Synthesis Kit (Invitrogen, Carlsbad, CA). Quantitative RT-PCR was performed in 96-well plates using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster, CA). Each reaction mixture consisted of 10 μL of Maxima SYBR Green/ROX qPCR Master Mix (2×) (Thermo Scientific, Foster, CA), 2 μL of forward and reverse primers (5 pmol each), 1 μL of complementary DNA (8 ng), and 7 μL of double-distilled water in a final volume of 20 μL. Oligonucleotide PCR primers for β2-microglobulin (assay ID AF072097) and HRV-4 (assay ID DQ473490.1) were purchased from Applied Biosystems. The PCR conditions were as follows: 50°C for 2 min, 95°C for 10 min, and then 50 cycles of 95°C for 15 s and 60°C for 30 s. mRNA expression level of target gene was normalized to mRNA expression level for the housekeeping gene β2-microglobulin and analyzed by the 2–ΔΔC T method using StepOne Software v2.1 and DataAssist Software (Applied Biosystems).
Cytotoxicity was expressed as 50% cytotoxic concentration (CC50) of the compound that reduced the viability of cells to 50% of the control. Fifty percent inhibitory concentration (IC50) was defined as the compound concentration required to reducing the viral CPE to 50% of the control. The CC50 and IC50 values were calculated using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). Therapeutic index was determined as the ratio of CC50 to IC50. Results were expressed as mean ± SD of triplicate samples of three independent experiments. Statistical analyses were carried out using SAS 9.13 program (SAS Institute, Cary, NC). Data from two groups were analyzed by a Student’s t-test, and multiple groups were analyzed by a one-way analysis of variance and Bonferroni multiple comparison test.
Anti-HRV activity of test compounds
Cytotoxicity and antiviral activity of ellagic acid and antiviral agent ribavirin toward human rhinovirus-4 in HeLa cells using sulforhodamine B bioassay
38 ± 3.2b
31 ± 5.2b
29 ± 2.5b
41 ± 1.1b
30 ± 2.4b
29 ± 1.7b
70 ± 4.9a
71 ± 0.5a
63 ± 5.6a
Effect on the infectivity of HRV particles
Time course of compound addition
Effect on the level of HRV replication
The current in vitro study indicates that materials derived from L. speciosa leaves exhibited antiviral activity and selectivity toward three rhinoviruses HRV-2, HRV-3, and HRV-4. The plant grows widely in tropical countries, including the Philippines, India, Malaysia, China, and Australia and is a popular folk medicine in Southeast Asia. L. speciosa leaves contain acetal, alkaloids, sterols, tannins, and triterpenoids[26, 27]. Excellent antidiabetic properties of a standardized extract from L. speciosa leaves have been well noted[28, 29].
Various compounds, including phenolics, terpenoids, and alkaloids, exist in plants, and jointly or independently they contribute to antiviral efficacy. Many plants and their constituents manifest antiviral activity toward different viruses[14, 30] and have been proposed as alternatives to conventional antiviral drugs. Anti-HRV constituents derived from plants include alkaloids (e.g., arborinine and (S)-ribalinine, IC50 3.19 and 82.95 μM; glaucine, IC50 22 μM), coumarins (e.g., 6,7,8-trimethoxycoumarin and daphnoretin methyl ether, IC50 11.98 and 97.08 μM; farnesiferol B and C, IC50 ≈ 2.61 μM), flavonoids (e.g., 4′,5-dihydroxy-3′,3,7-trimethoxyflavone, IC50 0.29 μM; 3-methylquercetin and three related compounds, effective concentration 15.8 μM; chrysosplenol D and others, minimum effective dose 0.22–33.3 μM); chrysosplenol C, IC50 0.75 μM), terpenoids (e.g., 3-O-trans-caffeoyltormentic acid, IC50 30.72 μM; orobol 7-O-D-glucoside, IC50 1.29–19.62 μM), organic acid (e.g., raoulic acid, IC50 0.51 μM; gallic acid, IC50 ≈ 294.55 μM), and thiosulfinates (allicin and allyl methylthiosulfinate). It has been reported that HRV capsid-binding compounds toward all HRV serotypes showed the existence of group A and B, based on a wide range of susceptibilities to antiviral compounds. In the current study, the antiviral principle was determined to be the tannin ellagic acid. The constituent exhibited antiviral activity toward both group A (HRV-2) and group B (HRV-3 and HRV-4). IC50 of ellagic acid was between 95.9 and 125.8 μM toward three HRVs, although IC50 of the natural compounds stated previously is between 0.22 and 294.55 μM. Ellagic acid exhibited greater antiviral activity than ribavirin toward three HRVs and high selectivity. This original finding indicates that materials derived from L. speciosa leaves can hold promise for the development of novel and effective naturally occurring antiviral agents for two different HRV groups (A and B). In addition, ellagic acid was reported to possess anti-HIV activity, through inhibition of HIV protease. Orobol 7-O-D-glucoside from L. speciosa leaves is also known to have broad-spectrum antiviral activity toward various HRVs including group A and B, as well as pleconaril-resistant HRV-5.
Investigations on the modes of antiviral action of naturally occurring compounds may contribute to the development of selective HRV therapeutic alternatives with novel target sites. The modes of anti-HRV action of plant secondary substances have been well reviewed by Rollinger and Schmidtke. Targeting virus molecules is likely more specific and less toxic, but there is a narrow spectrum of viruses and a higher risk of creating resistant viruses. On the contrary, chemicals which target cellular molecules may possess a broader antiviral activity spectrum and less risk of developing virus resistance, but may be more toxic to the host cell. In the current study, ellagic acid does not interact with the HRV-4 particles, as preexposure of the virus to the constituent did not alter the infectivity of HRV-4 particles. Based on time-of-addition experiments, ellagic acid significantly suppressed HRV-4 infection only when added just after the virus inoculation (0 h), but not before -1 h or after 1 h or later. This finding suggests that ellagic acid may directly interact with the human cells in the early stage of HRV infections to protect the cells from the virus destruction. In addition, RT-PCR analysis revealed that ellagic acid strongly inhibited the RNA replication of HRV-4 in HeLa system, suggesting that ellagic acid inhibit virus replication by targeting on cellular molecules, rather than virus molecules. Detailed tests are needed to fully understand the anti-HRV mode of action of ellagic acid.
L. speciosa leaf-derived preparations containing ellagic acid could be useful as an antiviral agent in the prevention or treatment of HRV infection. The antiviral action of ellagic acid may be an indication of at least one of the pharmacological actions of L. speciosa. For the practical use of L. speciosa leaf-derived preparations as novel anti-HRV products to proceed, further research is needed to establish their human safety and whether this activity is exerted in vivo after consumption of L. speciosa leaf-derived products by humans. Historically, a tea from the plant leaves has been used for the treatment of diabetes mellitus in the Philippines. Rats fed ellagic acid at doses as high as 50 mg/day up to 45 days did not cause any signs of systemic toxicity. Lastly, detailed tests are needed to understand how to improve anti-HRV potency and stability for eventual commercial development.
American type culture collection
- CC50 :
50% cytotoxic concentration
- CCID50 :
50% cell culture infective dose
- IC50 :
50% inhibitory concentration
Minimum essential medium
Thin layer chromatography.
This work was carried out with the support of the Brain Korea 21 PLUS through the National Research Foundation of Korea funded by the Ministry of Education of the Korean Government to Y.-J. Ahn.
- Heikkinen T, Jarvinen A: The common cold. Lancet. 2003, 361: 51-59. 10.1016/S0140-6736(03)12162-9.View ArticlePubMedGoogle Scholar
- Jacobs SE, Lamson DM, St George K, Walsh TJ: Human rhinoviruses. Clin Microbiol Rev. 2013, 26: 135-162. 10.1128/CMR.00077-12.View ArticlePubMedPubMed CentralGoogle Scholar
- Pitkaranta A, Virolainen A, Jero J, Arruda E, Hayden FG: Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics. 1998, 102: 291-295. 10.1542/peds.102.2.291.View ArticlePubMedGoogle Scholar
- Pitkaranta A, Arruda E, Malmberg H, Hayden FG: Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. J Clin Microbiol. 1997, 35: 1791-1793.PubMedPubMed CentralGoogle Scholar
- Abzug MJ, Beam AC, Gyorkos EA, Levin MJ: Viral pneumonia in the first month of life. Pediatr Infect Dis J. 1990, 9: 881-885. 10.1097/00006454-199012000-00005.View ArticlePubMedGoogle Scholar
- Duff AL, Pomeranz ES, Gelber LE, Price GW, Farris H, Hayden FG, Platts-Mills TA, Heymann PW: Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens. Pediatrics. 1993, 92: 535-540.PubMedGoogle Scholar
- Nicholson KG, Kent J, Ireland DC: Respiratory viruses and exacerbations of asthma in adults. British Med J. 1993, 307: 982-986. 10.1136/bmj.307.6910.982.View ArticleGoogle Scholar
- Rotbart HA: Treatment of picornavirus infections. Antiviral Res. 2002, 53: 83-98. 10.1016/S0166-3542(01)00206-6.View ArticlePubMedGoogle Scholar
- Waterer G, Wunderink R: Respiratory infections: a current and future threat. Respirology. 2009, 14: 651-655. 10.1111/j.1440-1843.2009.01554.x.View ArticlePubMedGoogle Scholar
- Turner RB: The treatment of rhinovirus infections: progress and potential. Antiviral Res. 2001, 49: 1-14. 10.1016/S0166-3542(00)00135-2.View ArticlePubMedGoogle Scholar
- Vlietinck AJ, Vanden Berghe DA: Can ethnopharmacology contribute to the development of antiviral drugs?. J Ethnopharmacol. 1991, 32: 141-153. 10.1016/0378-8741(91)90112-Q.View ArticlePubMedGoogle Scholar
- Cowan MM: Plant products as antimicrobial agents. Clin Microbiol Rev. 1999, 12: 564-582.PubMedPubMed CentralGoogle Scholar
- Williams JE: Review of antiviral and immunomodulating properties of plants of the Peruvian rainforest with a particular emphasis on Una de Gato and Sangre de Grado. Altern Med Rev. 2001, 6: 567-579.PubMedGoogle Scholar
- Jassim SA, Naji MA: Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol. 2003, 95: 412-427. 10.1046/j.1365-2672.2003.02026.x.View ArticlePubMedGoogle Scholar
- Miura T, Takagi S, Ishida T: Management of diabetes and its complications with banaba (Lagerstroemia speciosa L.) and corosolic acid. Evid Based Complement Alternat Med. 2012, doi:10.1155/2012/871495Google Scholar
- Suzuki Y, Unno T, Ushitani M, Hayasi K, Kakuda T: Manti obesity activity of extracts from Lagerstroemia speciosa L. leaves on female kk-Ay mice. J Nutr Sci Vitaminol. 1999, 45: 791-795. 10.3177/jnsv.45.791.View ArticlePubMedGoogle Scholar
- Unno T, Sakane I, Masumizu T, Kohno M, Kakuda T: Antioxidative activity of water extracts of Lagerstroemia speciosa leaves. Biosci Biotechnol Biochem. 1997, 61: 1772-1774. 10.1271/bbb.61.1772.View ArticlePubMedGoogle Scholar
- Unno T, Sugimoto A, Kakuda T: Xanthine oxidase inhibitors from leaves of Lagerstroemia speciosa (L.) Pers. J Ethnopharmacol. 2004, 93: 391-395. 10.1016/j.jep.2004.04.012.View ArticlePubMedGoogle Scholar
- Priya TT: Free radical scavenging and anti-inflammatory properties of Lagerstroemia speciosa. Inflammopharmacology. 2008, 16: 182-187. 10.1007/s10787-008-7002-6.View ArticlePubMedGoogle Scholar
- Ambujakdhi HR: Antibacterial activity of leaves of Lagerstroemia speciosa. J Pharm Res. 2009, 2: 1028-Google Scholar
- Graci JD, Cameron CE: Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol. 2006, 16: 37-48. 10.1002/rmv.483.View ArticlePubMedGoogle Scholar
- Vichai V, Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006, 1: 1112-1116. 10.1038/nprot.2006.179.View ArticlePubMedGoogle Scholar
- Choi HJ, Kim JH, Lee CH, Ahn YJ, Song JH, Baek SH, Kwon DH: Antiviral activity of quercetin 7-rhamnoside against porcine epidemic diarrhea virus. Antiviral Res. 2009, 81: 77-81. 10.1016/j.antiviral.2008.10.002.View ArticlePubMedGoogle Scholar
- Nawwar MAM, Souleman AMA: 3,4,8,9,10-Pentahydroxy-dibenzo[b, d]pyran-6-one from Tamarix nilotica. Phytochemistry. 1984, 23: 2966-2967. 10.1016/0031-9422(84)83057-5.View ArticleGoogle Scholar
- Chiang LC, Chiang W, Lin CC: In vitro antiviral activities of Caesalpinia pulcherrima and its related flavonoids. J Antimicrob Chemother. 2003, 52: 194-198. 10.1093/jac/dkg291.View ArticlePubMedGoogle Scholar
- Murakami C, Myoga K, Kasai R, Ohtani K, Kurokawa T, Ishibashi S, Dayrit F, Padolina WG, Yamasaki K: Screening of plant constituents for effect on glucose transport activity in Ehrlich ascites tumur cells. Chem Pharm Bull. 1993, 41: 2129-2131. 10.1248/cpb.41.2129.View ArticlePubMedGoogle Scholar
- Ragasa CY, Ngo HT, Rideout JA: Terpenoids and sterols from Lagerstroemia speciosa. J Asian Natural Prod Res. 2005, 7: 71-72. 10.1080/10286020310001595999.View ArticleGoogle Scholar
- Quisumbing E: Medicinal Plants of the Phillippines. 1978, Quezon, the Phillippines: Katha PublishingGoogle Scholar
- Judy WV, Hari SP, Stogsdill WW, Judy JS, Naguib YMA, Passwater R: Antidiabetic activity of a standardized extract (Glucosol™) from Lagerstroemia speciosa leaves in type II diabetics: a dose-dependence study. J Ethnopharmacol. 2003, 87: 115-117. 10.1016/S0378-8741(03)00122-3.View ArticlePubMedGoogle Scholar
- Liu AL, Du GH: Antiviral properties of phytochemicals. Dietary Phytochemical and Microbes. Edited by: Patra AK. 2012, New York: Springer, 93-126.View ArticleGoogle Scholar
- Rollinger JM, Schuster D, Danzl B, Schwaiger S, Markt P, Schmidtke M, Gertsch J, Raduner S, Wolber G, Langer T, Stuppner H: In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens L. Planta Med. 2009, 75: 195-204. 10.1055/s-0028-1088397.View ArticlePubMedGoogle Scholar
- Spasova M, Philipov S, Nikolaeva-Glomb L, Galabov AS, Milkova T: Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities. Bioorg Med Chem. 2008, 16: 7457-7461. 10.1016/j.bmc.2008.06.010.View ArticlePubMedGoogle Scholar
- Rollinger JM, Steindl TM, Schuster D, Kirchmair J, Anrain K, Ellmerer EP, Langer T, Stuppner H, Wutzler P, Schmidtke M: Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. J Med Chem. 2008, 51: 842-851. 10.1021/jm701494b.View ArticlePubMedGoogle Scholar
- Ishitsuka H, Ohsawa C, Ohiwa T, Umeda I, Suhara Y: Antipicornavirus flavone Ro 09–0179. Antimicrob Agents Chemother. 1982, 22: 611-616. 10.1128/AAC.22.4.611.View ArticlePubMedPubMed CentralGoogle Scholar
- Van Hoof L, Vanden Berghe DA, Hatfield GM, Vlietinck AJ: Plant antiviral agents V. 3-Methoxyflavones as potent inhibitors of viral-induced block of cell synthesis. Planta Med. 1984, 50: 513-517. 10.1055/s-2007-969786.View ArticleGoogle Scholar
- Tsuchiya Y, Shimizu M, Hiyama Y, Itoh K, Hashimoto Y, Nakayama M, Horie T, Morita N: Antiviral activity of natural occurring flavonoids in vitro. Chem Pharm Bull. 1985, 33: 3881-3886. 10.1248/cpb.33.3881.View ArticlePubMedGoogle Scholar
- Semple SJ, Nobbs SF, Pyke SM, Reynolds GD, Flower RL: Antiviral flavonoid from Pterocaulon sphacelatum, an Australian Aboriginal medicine. J Ethnopharmacol. 1999, 68: 283-288. 10.1016/S0378-8741(99)00050-1.View ArticlePubMedGoogle Scholar
- De Tommasi N, De Simone F, Pizza C, Mahmood N, Moore PS, Conti C, Orsi N, Stein ML: Constituents of Eriobotrya japonica: a study of their antiviral properties. J Nat Prod. 1992, 55: 1067-1073. 10.1021/np50086a006.View ArticlePubMedGoogle Scholar
- Choi HJ, Bae EY, Song JH, Baek SH, Kwon DH: Inhibitory effects of orobol 7-O-D-glucoside from banaba (Lagerstroemia speciosa L.) on human rhinovirus replication. Lett Appl Microbiol. 2010, 51: 1-5.PubMedGoogle Scholar
- Choi HJ, Lim CH, Song JH, Baek SH, Kwon DH: Antiviral activity of raoulic acid from Raoulia australis against Picornaviruses. Phytomedicine. 2009, 16: 35-39. 10.1016/j.phymed.2008.10.012.View ArticlePubMedGoogle Scholar
- Choi HJ, Song JH, Bhatt LR, Baek SH: Anti-human rhinovirus activity of gallic acid possessing antioxidant capacity. Phytother Res. 2010, 24: 1292-1296. 10.1002/ptr.3101.View ArticlePubMedGoogle Scholar
- Weber ND, Anderson DO, North JA, Murray BK, Lawson LD, Hughes BG: In vitro virucidal activity of Allium sativum (garlic) extract and compounds. Planta Med. 1992, 58: 417-423. 10.1055/s-2006-961504.View ArticlePubMedGoogle Scholar
- Andries K, Dewindt B, Snoeks J, Wouters L, Moereels H, Lewi PJ, Janssen AJ: Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol. 1990, 64: 1117-1123.PubMedPubMed CentralGoogle Scholar
- Nutan MM, Goel T, Das T, Malik S, Suri S, Rawat AKS, Srivastava SK, Tuli R, Malhotra S, Gupta SK: Ellagic acid & gallic acid from Lagerstroemia speciosa L. inhibit HIV-1 infection through inhibition of HIV-1 protease & reverse transcriptase activity. Indian J Med Res. 2013, 137: 540-548.PubMed CentralGoogle Scholar
- Rollinger JM, Schmidtke M: The human rhinovirus: human pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev. 2010, 31: 42-92.View ArticleGoogle Scholar
- Kitazato K, Wang Y, Kobayashi N: Viral infectious disease and natural products with antiviral activity. Drug Discov Ther. 2007, 1: 14-22.PubMedGoogle Scholar
- Doyle B, Griffiths LA: The metabolism of ellagic acid in the rat. Xenobiotica. 1980, 10: 247-256. 10.3109/00498258009033752.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/171/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.